Alaethes Wealth’s ImmunityBio IBRX Stock Holding History

Alaethes Wealth’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-5,175	Closed	-$29K	–	195
2022 Q1	$29K	Hold	5,175	–	–	0.02%	152
2021 Q4	$31K	Hold	5,175	–	–	0.02%	148
2021 Q3	$50K	Hold	5,175	–	–	0.04%	134
2021 Q2	$74K	Buy	+5,175	New	+$85.5K	0.06%	114

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Alaethes Wealth's IBRX Position: Q2 2022 in Review

Alaethes Wealth sold out of ImmunityBio (IBRX) in Q2 2022, closing a stake of 5,175 shares — an estimated $29K sold.

Alaethes Wealth first reported a position in IBRX in Q2 2021 and held it in 4 quarters. The position peaked at $74K in Q2 2021. 131 funds tracked by Wall St. Rank hold IBRX as of Q2 2022.

Alaethes Wealth reported no remaining ImmunityBio position as of Q2 2022 after selling out during the quarter.
Alaethes Wealth sold 5,175 ImmunityBio shares in Q2 2022, an estimated $29K.
Alaethes Wealth first reported a position in ImmunityBio in Q2 2021 and held it in 4 quarters.
Alaethes Wealth's ImmunityBio position peaked at $74K in Q2 2021.
131 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2022.

Based on Alaethes Wealth's 13F filing for Q2 2022, filed 16 Aug 2022.